Conan Chua, Aman Mehrotra, Dr. Adam Gehring,
Toronto Centre for Liver Disease, Toronto, Ontario, Canada
During a traditional FluroSpot assay, low HBV Specific T cell frequencies have hindered effective ex vivo analysis. We overcame this obstacle to measure ex vivo T cell responses in CHB patients, by modifying the key variables of cell number and the peptide pulsing method to improve ex vivo detection of HBV-specific T cells.
You can access the full protocol here: